Experiences in fragment-based drug discovery.
暂无分享,去创建一个
[1] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[2] James M. Woolven,et al. Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. , 2012, Journal of medicinal chemistry.
[3] S. Rabindran,et al. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors. , 2011, Journal of medicinal chemistry.
[4] David S. Millan,et al. Fragment based discovery of a novel and selective PI3 kinase inhibitor. , 2011, Bioorganic & medicinal chemistry letters.
[5] Michael Czarniecki,et al. Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors. , 2010, Journal of medicinal chemistry.
[6] Gianni Chessari,et al. Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. , 2008, Journal of medicinal chemistry.
[7] Marcel L Verdonk,et al. Group Efficiency: A Guideline for Hits‐to‐Leads Chemistry , 2008, ChemMedChem.
[8] Christopher W. Murray,et al. Assessing the lipophilicity of fragments and early hits , 2011, J. Comput. Aided Mol. Des..
[9] I. D. de Esch,et al. Surface plasmon resonance biosensor based fragment screening using acetylcholine binding protein identifies ligand efficiency hot spots (LE hot spots) by deconstruction of nicotinic acetylcholine receptor α7 ligands. , 2010, Journal of medicinal chemistry.
[10] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[11] W. Jencks,et al. Entropic contributions to rate accelerations in enzymic and intramolecular reactions and the chelate effect. , 1971, Proceedings of the National Academy of Sciences of the United States of America.
[12] Hans Briem,et al. A crystallographic fragment screen identifies cinnamic acid derivatives as starting points for potent Pim-1 inhibitors. , 2011, Acta crystallographica. Section D, Biological crystallography.
[13] Gerhard Klebe,et al. A small nonrule of 3 compatible fragment library provides high hit rate of endothiapepsin crystal structures with various fragment chemotypes. , 2011, Journal of medicinal chemistry.
[14] David M. Wilson,et al. Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. , 2012, Journal of medicinal chemistry.
[15] Rob Leurs,et al. Transforming fragments into candidates: small becomes big in medicinal chemistry. , 2009, Drug discovery today.
[16] Gerhard Klebe,et al. Fragment‐Based Lead Discovery: Screening and Optimizing Fragments for Thermolysin Inhibition , 2010, ChemMedChem.
[17] Peter Brandt,et al. Deconstruction of non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1 for exploration of the optimization landscape of fragments. , 2011, Journal of medicinal chemistry.
[18] A. Tanner,et al. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors. , 2011, Journal of medicinal chemistry.
[19] Rob Leurs,et al. Fragment growing induces conformational changes in acetylcholine-binding protein: a structural and thermodynamic analysis. , 2011, Journal of the American Chemical Society.
[20] R. Smits,et al. Fragment library screening reveals remarkable similarities between the G protein-coupled receptor histamine H4 and the ion channel serotonin 5-HT3A , 2011, Bioorganic & medicinal chemistry letters.
[21] Hans Matter,et al. Fragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexes. , 2012, Angewandte Chemie.
[22] Qiyue Hu,et al. Novel isoquinolone PDK1 inhibitors discovered through fragment-based lead discovery , 2011, J. Comput. Aided Mol. Des..
[23] Gianni Chessari,et al. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. , 2010, Journal of medicinal chemistry.
[24] A. Fersht,et al. Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. , 2010, Chemistry & biology.
[25] B. Davis,et al. Structure-guided design of alpha-amino acid-derived Pin1 inhibitors. , 2009, Bioorganic & medicinal chemistry letters.
[26] M. Drysdale,et al. Medicinal chemistry of Hsp90 inhibitors. , 2008, Current topics in medicinal chemistry.
[27] J. T. Metz,et al. Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.
[28] Mark Whittaker,et al. Discovery of a Novel Hsp90 Inhibitor by Fragment Linking , 2010, ChemMedChem.
[29] A. Good,et al. The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors. , 2011, Bioorganic & medicinal chemistry letters.
[30] James E Audia,et al. Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor , 2011, The Journal of Neuroscience.
[31] C. Murray,et al. Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models , 2011, Molecular Cancer Therapeutics.
[32] W. Jahnke,et al. Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery. , 2010, Nature chemical biology.
[33] Saul H Rosenberg,et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. , 2008, Journal of medicinal chemistry.
[34] J. Praly,et al. Binding evaluation of fragment-based scaffolds for probing allosteric enzymes. , 2012, Journal of medicinal chemistry.
[35] Daniel A Erlanson,et al. Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery. , 2011, Bioorganic & medicinal chemistry letters.
[36] James E. J. Mills,et al. Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics , 2011, J. Comput. Aided Mol. Des..
[37] Stuart L Schreiber,et al. Organic synthesis toward small-molecule probes and drugs , 2011, Proceedings of the National Academy of Sciences.
[38] Gianni Chessari,et al. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. , 2010, Journal of medicinal chemistry.
[39] M. Uesugi,et al. [Discovering high-affinity ligands for proteins: SAR by NMR]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.
[40] Christopher A Lepre,et al. Practical aspects of NMR-based fragment screening. , 2011, Methods in enzymology.
[41] Karl A. Walter,et al. ChemInform Abstract: Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR. , 1997 .
[42] Kam Y. J. Zhang,et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.
[43] P. Leeson,et al. A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.
[44] Yuan Cheng,et al. From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1). , 2011, Journal of medicinal chemistry.
[45] Paul G Wyatt,et al. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. , 2008, Journal of medicinal chemistry.
[46] S. Barelier,et al. Fragment-based deconstruction of Bcl-xL inhibitors. , 2010, Journal of medicinal chemistry.
[47] Xiang Li,et al. Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. , 2011, Journal of medicinal chemistry.
[48] A. Leach,et al. Molecular complexity and fragment-based drug discovery: ten years on. , 2011, Current opinion in chemical biology.
[49] C. Abell,et al. A fragment-based approach to identifying ligands for riboswitches. , 2010, ACS chemical biology.
[50] Warren R. J. D. Galloway,et al. Drug discovery: A question of library design , 2011, Nature.
[51] Doris Hafenbradl,et al. A comparative study of fragment screening methods on the p38α kinase: new methods, new insights , 2011, J. Comput. Aided Mol. Des..
[52] Kerim Babaoglu,et al. Deconstructing fragment-based inhibitor discovery , 2006, Nature chemical biology.
[53] S. Korsmeyer,et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.
[54] György M. Keserü,et al. The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.
[55] Gianni Chessari,et al. Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. , 2006, Journal of medicinal chemistry.
[56] Paul D. Leeson,et al. The influence of the 'organizational factor' on compound quality in drug discovery , 2011, Nature Reviews Drug Discovery.
[57] I. Kuntz,et al. The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[58] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[59] C. Murray,et al. The rise of fragment-based drug discovery. , 2009, Nature chemistry.
[60] Claudio Luchinat,et al. Entropic contribution to the linking coefficient in fragment based drug design: a case study. , 2010, Journal of medicinal chemistry.
[61] Mladen Vinković,et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. , 2009, Journal of medicinal chemistry.
[62] Paul Bamborough,et al. Selectivity of kinase inhibitor fragments. , 2011, Journal of medicinal chemistry.
[63] J. Mestan,et al. Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. , 2010, Journal of the American Chemical Society.
[64] Marcel L Verdonk,et al. Identification of inhibitors of protein kinase B using fragment-based lead discovery. , 2007, Journal of medicinal chemistry.
[65] Lingyan Wang,et al. Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation. , 2010, Journal of medicinal chemistry.
[66] T. Blundell,et al. Structural biology in fragment-based drug design. , 2010, Current opinion in structural biology.
[67] F. Giordanetto,et al. Discovery of novel class 1 phosphatidylinositide 3-kinases (PI3K) fragment inhibitors through structure-based virtual screening. , 2011, Bioorganic & medicinal chemistry letters.
[68] Andrew L Hopkins,et al. Fragment screening by surface plasmon resonance. , 2010, ACS medicinal chemistry letters.
[69] Denise G. Teotico,et al. Docking for fragment inhibitors of AmpC β-lactamase , 2009, Proceedings of the National Academy of Sciences.
[70] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[71] Gregg Siegal,et al. Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. , 2011, Methods in enzymology.
[72] Anthony M Giannetti,et al. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance. , 2011, Methods in enzymology.
[73] Christopher W Murray,et al. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. , 2005, Journal of medicinal chemistry.
[74] Ian Collins,et al. Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. , 2008, Journal of medicinal chemistry.
[75] J. E. Elder,et al. Fragment‐Based Screen against HIV Protease , 2010, Chemical biology & drug design.
[76] J. Briand,et al. Aminoindazole PDK1 Inhibitors: A Case Study in Fragment-Based Drug Discovery. , 2010, ACS medicinal chemistry letters.
[77] Marcel L. Verdonk,et al. The consequences of translational and rotational entropy lost by small molecules on binding to proteins , 2002, J. Comput. Aided Mol. Des..
[78] Roy J. Vaz,et al. Fragment screening of inhibitors for MIF tautomerase reveals a cryptic surface binding site. , 2010, Bioorganic & medicinal chemistry letters.
[79] Gabriele Varani,et al. A small-molecule probe induces a conformation in HIV TAR RNA capable of binding drug-like fragments. , 2011, Journal of molecular biology.
[80] Zhijian Zhao,et al. High concentration electrophysiology-based fragment screen: discovery of novel acid-sensing ion channel 3 (ASIC3) inhibitors. , 2011, Bioorganic & medicinal chemistry letters.
[81] Peter Brandt,et al. Identification of a novel scaffold for allosteric inhibition of wild type and drug resistant HIV-1 reverse transcriptase by fragment library screening. , 2011, Journal of medicinal chemistry.
[82] Andrew R. Leach,et al. Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..
[83] Christopher W Murray,et al. Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.
[84] R. Stevens,et al. Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. , 2011, Journal of medicinal chemistry.
[85] B. Davis,et al. Discovery of cell-active phenyl-imidazole Pin1 inhibitors by structure-guided fragment evolution. , 2011, Bioorganic & medicinal chemistry letters.
[86] Chris Abell,et al. Optimization of the interligand Overhauser effect for fragment linking: application to inhibitor discovery against Mycobacterium tuberculosis pantothenate synthetase. , 2010, Journal of the American Chemical Society.
[87] Renaldo Mendoza,et al. Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. , 2010, Bioorganic & medicinal chemistry letters.
[88] Gianni Chessari,et al. Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. , 2007, Journal of medicinal chemistry.
[89] P. Clemons,et al. Route to three-dimensional fragments using diversity-oriented synthesis , 2011, Proceedings of the National Academy of Sciences.
[90] Hoan Vu,et al. Fragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitors. , 2010, The Biochemical journal.
[91] B. Shoichet,et al. Molecular docking and ligand specificity in fragment-based inhibitor discovery. , 2009, Nature chemical biology.
[92] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[93] Lorenz C. Blum,et al. 970 million druglike small molecules for virtual screening in the chemical universe database GDB-13. , 2009, Journal of the American Chemical Society.